Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,438 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 669 · Balance 7,438 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Child 1 | 0 |
Reported balance
After 2025-02-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 2 | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 3 | 0 |
Reported balance
After 2025-02-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-02-19 · Other · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-19 transaction · row 6
2 source rows · reconciled sequenceRow 5 · 2025-02-19 · Grant · Acquired 20,393 · Balance 717,637 F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. Row 6 · 2025-02-19 · Other · Disposed 717,637 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.00 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-19 · Disposition to issuer · Disposed 36,085 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.44 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Disposition to issuer · Disposed 44,693 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance.
F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2021 Filed Jun 21, 2021 18:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,001 | $91.41 | $91,504.71 |
DisclosureSEC source: 0001562180-21-004388 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,710 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.86 to $91.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 18:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,233 | $93.22 | $114,935.94 |
DisclosureSEC source: 0001562180-21-004388 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,611 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $92.89 to $93.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 18:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,866 | $92.47 | $542,450.72 |
DisclosureSEC source: 0001562180-21-004388 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,844 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $91.86 to $92.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 18:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 900 | $89.86 | $80,873.01 |
DisclosureSEC source: 0001562180-21-004388 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,711 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $89.63 to $90.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 21, 2021 19:00 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001562180-21-003690 · primarydocument.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,434 Underlying: Common Stock · 10,000 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested with respected with 25% and vest with respect to the remaining shares in 36 equal monthly installment there after Read SEC document |
| May 20, 2021 Filed May 21, 2021 19:00 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 10,000 | $0.43 | $4,284.00 |
DisclosureSEC source: 0001562180-21-003690 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,391 | $83.38 | $282,730.73 |
DisclosureSEC source: 0001562180-21-003674 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,611 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $83.18 to $83.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,109 | $82.67 | $339,708.70 |
DisclosureSEC source: 0001562180-21-003674 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,002 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $82.16 to $83.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,500 | $81.69 | $122,530.05 |
DisclosureSEC source: 0001562180-21-003674 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,111 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.15 to $82.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 264 | $104.00 | $27,456.92 |
DisclosureSEC source: 0001562180-21-002900 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,611 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $103.99 to $104.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 7,422 | $103.27 | $766,442.48 |
DisclosureSEC source: 0001562180-21-002900 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,875 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $102.94 to $103.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,314 | $102.51 | $134,699.85 |
DisclosureSEC source: 0001562180-21-002900 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,297 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $101.93 to $102.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 360 | $109.21 | $39,315.60 |
DisclosureSEC source: 0001562180-21-002602 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,611 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units - April 1,2021 Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 572 | $111.07 | $63,529.81 |
DisclosureSEC source: 0001562180-21-002390 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,971 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $110.99 to $111.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,485 | $110.55 | $274,721.97 |
DisclosureSEC source: 0001562180-21-002390 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,543 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $109.98 to $110.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,400 | $109.56 | $262,932.96 |
DisclosureSEC source: 0001562180-21-002390 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,028 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $108.97 to $109.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,143 | $108.43 | $232,360.35 |
DisclosureSEC source: 0001562180-21-002390 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,428 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $107.91 to $108.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,400 | $106.89 | $149,646.00 |
DisclosureSEC source: 0001562180-21-002390 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $106.72 to $107.30 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 22:32 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001562180-21-002379 · primarydocument.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,100 Underlying: Common Stock · 20,000 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is vested and exercisable as to 201,100 shares, and the remaining shares will vest and become exercisable in equal monthly installments until May 3, 2022. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 22:32 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 20,000 | $0.43 | $8,568.00 |
DisclosureSEC source: 0001562180-21-002379 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,020 | $119.38 | $121,767.19 |
DisclosureSEC source: 0001562180-21-001517 · primarydocument.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,971 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $119.31 to $119.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,507 | $118.62 | $178,755.97 |
DisclosureSEC source: 0001562180-21-001517 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,991 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $118.25 to $119.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,672 | $117.67 | $549,755.64 |
DisclosureSEC source: 0001562180-21-001517 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,498 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.25 to $118.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,501 | $116.48 | $174,838.43 |
DisclosureSEC source: 0001562180-21-001517 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,170 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $116.13 to $116.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $115.04 | $34,512.00 |
DisclosureSEC source: 0001562180-21-001517 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,671 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| February 11, 2021 Filed Feb 24, 2021 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 16,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001517 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,971 F1 · shares: 2021 Annual RSU grant - vesting Commencement date Jan-1-2021, 1/16th of the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 311 | $98.75 | $30,709.97 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 15 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,941 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F13 · price: This transaction was executed in multiple trades at prices ranging from $98.51 to $99.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 923 | $98.16 | $90,605.10 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 14 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,252 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $97.45 to $98.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 666 | $96.64 | $64,360.97 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 13 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,175 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $96.06 to $97.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 700 | $95.24 | $66,667.02 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 12 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,841 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $94.89 to $95.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $94.32 | $37,729.00 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 11 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,541 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $93.88 to $94.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 601 | $98.71 | $59,325.01 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 10 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,941 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $98.49 to $98.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 599 | $97.97 | $58,683.37 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 9 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,542 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $97.45 to $98.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $96.69 | $58,014.00 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 8 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,141 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $96.16 to $96.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 800 | $95.23 | $76,187.04 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 7 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,741 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $94.89 to $95.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $94.32 | $37,729.00 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,541 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $93.88 to $94.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $98.72 | $59,229.00 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,941 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $98.50 to $99.08 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $97.95 | $58,767.00 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,541 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $97.45 to $98.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $96.69 | $58,015.02 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,141 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $96.11 to $96.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 900 | $95.38 | $85,840.02 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,741 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $94.89 to $95.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $94.21 | $28,262.01 |
DisclosureSEC source: 0001562180-21-000383 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,641 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $93.88 to $94.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 22:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $97.49 | $29,246.01 |
DisclosureSEC source: 0001562180-21-000353 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,941 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $97.39 to $97.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 22:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,701 | $96.63 | $357,642.06 |
DisclosureSEC source: 0001562180-21-000353 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,241 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $96.17 to $97.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 22:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 9,007 | $95.76 | $862,540.94 |
DisclosureSEC source: 0001562180-21-000353 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,942 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $95.15 to $96.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 22:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,547 | $94.70 | $619,996.97 |
DisclosureSEC source: 0001562180-21-000353 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,949 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $94.12 to $95.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 22:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 8,045 | $93.70 | $753,779.49 |
DisclosureSEC source: 0001562180-21-000353 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $93.12 to $94.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:46 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 610 | $82.78 | $50,497.69 |
DisclosureSEC source: 0001562180-21-000256 · primarydocument.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,541 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $82.66 to $83.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:46 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,215 | $81.86 | $345,031.89 |
DisclosureSEC source: 0001562180-21-000256 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,151 F6 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $81.59 to $82.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:46 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,175 | $81.23 | $257,894.14 |
DisclosureSEC source: 0001562180-21-000256 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,366 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $80.59 to $81.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:46 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,600 | $80.07 | $368,323.38 |
DisclosureSEC source: 0001562180-21-000256 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,541 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $79.57 to $80.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.